Circulation. 2002;105:1756-1759
Published online before print April 1, 2002, doi: 10.1161/01.CIR.0000015465.73933.3B
Published online before print April 1, 2002, doi: 10.1161/01.CIR.0000015465.73933.3B
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2002;105:1756.)
© 2002 American Heart Association, Inc.
Brief Rapid Communications |
Statin Prevents Tissue Factor Expression in Human Endothelial Cells
Role of Rho/Rho-Kinase and Akt Pathways
From the Division of Cardiology (M.E., T.K., F.C, T.F.L.), CardioVascular Center, University Hospital and Cardiovascular Research (M.E., T.K., F.C., H.J., T.F.L.), Institute of Physiology, University of Zurich, Zurich, Switzerland; the Department of Experimental Medicine and Pathology (F.C.), "La Sapienza" University, Rome, Italy; and Department of Neuromed (F.C.), Pozzilli, Italy.
Correspondence to Thomas F. Lüscher, MD, Division of Cardiology, University Hospital, Ramistrasse 100, CH-8091 Zurich, Switzerland. E-mail cardiotfl{at}gmx.ch
Background— Tissue factor plays a pivotal role in thrombus formation in acute coronary syndromes. However, the regulatory mechanisms underlying tissue factor expression are poorly understood. Statins are effective in patients with acute coronary syndromes. Hence, the aim of this study was to clarify in human endothelial cells the signaling pathways of thrombin-induced tissue factor expression and potential inhibitory effects of statins.
Methods and Results— In human aortic endothelial cells, simvastatin prevented tissue factor induction by thrombin (4 U/mL) in a concentration-dependent manner. The increase in tissue factor activity on the cell surface was also blocked by simvastatin. Simvastatin also prevented the upregulation of tissue factor expression and activity in human aortic smooth muscle cells. Mevalonate (100 µmol/L) reversed the inhibitory effect of simvastatin on tissue factor expression. Thrombin induced rapid activation of Rho A and p38 MAP kinase. The Rho-kinase inhibitor Y-27632 and the p38 MAP kinase inhibitor SB203580 prevented tissue factor induction. Akt was dephosphorylated by thrombin; the phosphoinositol 3-kinase inhibitor wortmannin enhanced its dephosphorylation as well as thrombin-induced tissue factor expression. Simvastatin prevented thrombin-induced Rho A activation but not p38 MAP kinase activation. Akt dephosphorylation by thrombin was blocked by both simvastatin and Y-27632.
Conclusions— Endothelial tissue factor induction by thrombin is regulated by Rho/Rho-kinase, Akt, and p38 MAP kinase. Simvastatin prevents its induction through inhibition of Rho/Rho-kinase and activation of Akt. These findings provide new insights into the action of statins in acute coronary syndromes.
Key Words: endothelium • pharmacology • signal transduction • thrombosis
This article has been cited by other articles:
 |
|
 |
|
  M. Rodriguez-Yanez, J. Agulla, R. Rodriguez-Gonzalez, T. Sobrino, and J. Castillo Review: Statins and stroke Therapeutic Advances in Cardiovascular Disease, June 1, 2008; 2(3): 157 - 166. [Abstract] [PDF]
|
|
|
|
 |
|
 T. F. Luscher and J. Steffel Sweet and Sour: Unraveling Diabetic Vascular Disease Circ. Res., January 4, 2008; 102(1): 9 - 11. [Full Text] [PDF]
|
|
|
|
|
|
M. J. Romero, D. H. Platt, H. E. Tawfik, M. Labazi, A. B. El-Remessy, M. Bartoli, R. B. Caldwell, and R. W. Caldwell Diabetes-induced Coronary Vascular Dysfunction Involves Increased Arginase Activity Circ. Res., January 4, 2008; 102(1): 95 - 102. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Zhang, Z. G. Zhang, X. S. Liu, A. Hozeska-Solgot, and M. Chopp The PI3K/Akt Pathway Mediates the Neuroprotective Effect of Atorvastatin in Extending Thrombolytic Therapy After Embolic Stroke in the Rat Arterioscler. Thromb. Vasc. Biol., November 1, 2007; 27(11): 2470 - 2475. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. A. Ferreira, T. P. Navarro, R. W. Telles, L. E. C. Andrade, and E. I. Sato Atorvastatin therapy improves endothelial-dependent vasodilation in patients with systemic lupus erythematosus: an 8 weeks controlled trial Rheumatology, October 1, 2007; 46(10): 1560 - 1565. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-R. Weng, C.-H. Tsai, S. K. Kulp, D. Wang, C.-H. Lin, H.-C. Yang, Y. Ma, A. Sargeant, C.-F. Chiu, M.-H. Tsai, et al. A Potent Indole-3-Carbinol Derived Antitumor Agent with Pleiotropic Effects on Multiple Signaling Pathways in Prostate Cancer Cells Cancer Res., August 15, 2007; 67(16): 7815 - 7824. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Bulhak, J. Roy, U. Hedin, P.-O. Sjoquist, and J. Pernow Cardioprotective effect of rosuvastatin in vivo is dependent on inhibition of geranylgeranyl pyrophosphate and altered RhoA membrane translocation Am J Physiol Heart Circ Physiol, June 1, 2007; 292(6): H3158 - H3163. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. R. Steinhubl, J. J. Badimon, D. L. Bhatt, J.-M. Herbert, and T. F. Luscher Clinical evidence for anti-inflammatory effects of antiplatelet therapy in patients with atherothrombotic disease Vascular Medicine, May 1, 2007; 12(2): 113 - 122. [Abstract] [PDF]
|
|
|
|
 |
|
 S. C. Fagan, H. F. Elewa, and D. J. Rychly Statin Therapy for Secondary Stroke Prevention: Evidence Catches Up to Practice Journal of Pharmacy Practice, April 1, 2007; 20(2): 117 - 122. [Abstract] [PDF]
|
|
|
|
|
|
Y. Mukai, C.-Y. Wang, Y. Rikitake, and J. K. Liao Phosphatidylinositol 3-kinase/protein kinase Akt negatively regulates plasminogen activator inhibitor type 1 expression in vascular endothelial cells Am J Physiol Heart Circ Physiol, April 1, 2007; 292(4): H1937 - H1942. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Camino-Lopez, V. Llorente-Cortes, J. Sendra, and L. Badimon Tissue factor induction by aggregated LDL depends on LDL receptor-related protein expression (LRP1) and Rho A translocation in human vascular smooth muscle cells Cardiovasc Res, January 1, 2007; 73(1): 208 - 216. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. N. Boushra and M. Muntazar Review article: The role of statins in reducing perioperative cardiac risk: physiologic and clinical perspectives: [Le role des statines dans la reduction du risque cardiaque perioperatoire : perspectives physiologiques et cliniques]. Can J Anesth, November 1, 2006; 53(11): 1126 - 1147. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. G. Camici, J. Steffel, A. Akhmedov, N. Schafer, J. Baldinger, U. Schulz, K. Shojaati, C. M. Matter, Z. Yang, T. F. Luscher, et al. Dimethyl Sulfoxide Inhibits Tissue Factor Expression, Thrombus Formation, and Vascular Smooth Muscle Cell Activation: A Potential Treatment Strategy for Drug-Eluting Stents Circulation, October 3, 2006; 114(14): 1512 - 1521. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Lin, A. Hamik, R. Jain, A. Kumar, and M. K. Jain Kruppel-Like Factor 2 Inhibits Protease Activated Receptor-1 Expression and Thrombin-Mediated Endothelial Activation Arterioscler. Thromb. Vasc. Biol., May 1, 2006; 26(5): 1185 - 1185. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. S. BelAiba, T. Djordjevic, S. Bonello, F. Artunc, F. Lang, J. Hess, and A. Gorlach The Serum- and Glucocorticoid-Inducible Kinase Sgk-1 Is Involved in Pulmonary Vascular Remodeling: Role in Redox-Sensitive Regulation of Tissue Factor by Thrombin Circ. Res., March 31, 2006; 98(6): 828 - 836. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Lopez-Pedrera, P Buendia, M A Aguirre, F Velasco, and M J Cuadrado Antiphospholipid syndrome and tissue factor: a thrombotic couple Lupus, March 1, 2006; 15(3): 161 - 166. [Abstract] [PDF]
|
|
|
|
|
|
G. Loirand, P. Guerin, and P. Pacaud Rho Kinases in Cardiovascular Physiology and Pathophysiology Circ. Res., February 17, 2006; 98(3): 322 - 334. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Steffel, T. F. Luscher, and F. C. Tanner Tissue Factor in Cardiovascular Diseases: Molecular Mechanisms and Clinical Implications Circulation, February 7, 2006; 113(5): 722 - 731. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Cao, N. Dronadula, and G. N. Rao Thrombin induces expression of FGF-2 via activation of PI3K-Akt-Fra-1 signaling axis leading to DNA synthesis and motility in vascular smooth muscle cells Am J Physiol Cell Physiol, January 1, 2006; 290(1): C172 - C182. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Kozai, M. Eto, Z. Yang, H. Shimokawa, and T. F. Luscher Statins prevent pulsatile stretch-induced proliferation of human saphenous vein smooth muscle cells via inhibition of Rho/Rho-kinase pathway Cardiovasc Res, December 1, 2005; 68(3): 475 - 482. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Zhang, Z. G. Zhang, G. L. Ding, Q. Jiang, X. Liu, H. Meng, A. Hozeska, C. Zhang, L. Li, D. Morris, et al. Multitargeted Effects of Statin-Enhanced Thrombolytic Therapy for Stroke With Recombinant Human Tissue-Type Plasminogen Activator in the Rat Circulation, November 29, 2005; 112(22): 3486 - 3494. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. K. Ray and C. P. Cannon The Potential Relevance of the Multiple Lipid-Independent (Pleiotropic) Effects of Statins in the Management of Acute Coronary Syndromes J. Am. Coll. Cardiol., October 18, 2005; 46(8): 1425 - 1433. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T Koike and T Atsumi Antiphospholipid antibodies and cell activation: crucial role of p38 MAPK pathway Lupus, October 1, 2005; 14(10): 799 - 801. [PDF]
|
|
|
|
|
|
J. Steffel, R. A. Latini, A. Akhmedov, D. Zimmermann, P. Zimmerling, T. F. Luscher, and F. C. Tanner Rapamycin, but Not FK-506, Increases Endothelial Tissue Factor Expression: Implications for Drug-Eluting Stent Design Circulation, September 27, 2005; 112(13): 2002 - 2011. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Eto, A. Kouroedov, F. Cosentino, and T. F. Luscher Glycogen Synthase Kinase-3 Mediates Endothelial Cell Activation by Tumor Necrosis Factor-{alpha} Circulation, August 30, 2005; 112(9): 1316 - 1322. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S.-Q. Wu and W. C. Aird Thrombin, TNF-{alpha}, and LPS exert overlapping but nonidentical effects on gene expression in endothelial cells and vascular smooth muscle cells Am J Physiol Heart Circ Physiol, August 1, 2005; 289(2): H873 - H885. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Steffel, A. Akhmedov, H. Greutert, T. F. Luscher, and F. C. Tanner Histamine Induces Tissue Factor Expression: Implications for Acute Coronary Syndromes Circulation, July 19, 2005; 112(3): 341 - 349. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Szotowski, P. Goldin-Lang, S. Antoniak, V. Y. Bogdanov, D. Pathirana, M. Pauschinger, A. Dorner, U. Kuehl, S. Coupland, Y. Nemerson, et al. Alterations in myocardial tissue factor expression and cellular localization in dilated cardiomyopathy J. Am. Coll. Cardiol., April 5, 2005; 45(7): 1081 - 1089. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Steffel, M. Hermann, H. Greutert, S. Gay, T. F. Luscher, F. Ruschitzka, and F. C. Tanner Celecoxib Decreases Endothelial Tissue Factor Expression Through Inhibition of c-Jun Terminal NH2 Kinase Phosphorylation Circulation, April 5, 2005; 111(13): 1685 - 1689. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Senokuchi, T. Matsumura, M. Sakai, M. Yano, T. Taguchi, T. Matsuo, K. Sonoda, D. Kukidome, K. Imoto, T. Nishikawa, et al. Statins Suppress Oxidized Low Density Lipoprotein-induced Macrophage Proliferation by Inactivation of the Small G Protein-p38 MAPK Pathway J. Biol. Chem., February 25, 2005; 280(8): 6627 - 6633. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Undas, K. E. Brummel-Ziedins, and K. G. Mann Statins and Blood Coagulation Arterioscler. Thromb. Vasc. Biol., February 1, 2005; 25(2): 287 - 294. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Kilic, U. Kilic, C. M. Matter, T. F. Luscher, C. L. Bassetti, and D. M. Hermann Aggravation of Focal Cerebral Ischemia by Tissue Plasminogen Activator Is Reversed by 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitor but Does Not Depend on Endothelial NO Synthase Stroke, February 1, 2005; 36(2): 332 - 336. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. O. Harrington, J. Newton, N. Morin, and S. Rounds Barrier dysfunction and RhoA activation are blunted by homocysteine and adenosine in pulmonary endothelium Am J Physiol Lung Cell Mol Physiol, December 1, 2004; 287(6): L1091 - L1097. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Tunon, L. M. Blanco-Colio, J. L. Martin-Ventura, and J. Egido Intensive treatment with statins and the progression of cardiovascular diseases: the beginning of a new era? Nephrol. Dial. Transplant., November 1, 2004; 19(11): 2696 - 2699. [Full Text] [PDF]
|
|
|
|
 |
|
 M. Bohgaki, T. Atsumi, Y. Yamashita, S. Yasuda, Y. Sakai, A. Furusaki, T. Bohgaki, O. Amengual, Y. Amasaki, and T. Koike The p38 mitogen-activated protein kinase (MAPK) pathway mediates induction of the tissue factor gene in monocytes stimulated with human monoclonal anti-{beta}2Glycoprotein I antibodies Int. Immunol., November 1, 2004; 16(11): 1633 - 1641. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.D. Loike, D.Y. Shabtai, R. Neuhut, S. Malitzky, E. Lu, J. Husemann, I.J. Goldberg, and S.C. Silverstein Statin Inhibition of Fc Receptor-Mediated Phagocytosis by Macrophages Is Modulated by Cell Activation and Cholesterol Arterioscler. Thromb. Vasc. Biol., November 1, 2004; 24(11): 2051 - 2056. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Becker and M. Chopp Role of Statins in the Treatment and Prevention of Stroke: Introduction Stroke, November 1, 2004; 35(11_suppl_1): 2706 - 2707. [Full Text] [PDF]
|
|
|
|
|
|
Y. Liu, K. Pelekanakis, and M. J. Woolkalis Thrombin and Tumor Necrosis Factor {alpha} Synergistically Stimulate Tissue Factor Expression in Human Endothelial Cells: REGULATION THROUGH c-Fos AND c-Jun J. Biol. Chem., August 20, 2004; 279(34): 36142 - 36147. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Solovey, R. Kollander, A. Shet, L. C. Milbauer, S. Choong, A. Panoskaltsis-Mortari, B. R. Blazar, R. J. Kelm Jr, and R. P. Hebbel Endothelial cell expression of tissue factor in sickle mice is augmented by hypoxia/reoxygenation and inhibited by lovastatin Blood, August 1, 2004; 104(3): 840 - 846. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
U. Schonbeck and P. Libby Inflammation, Immunity, and HMG-CoA Reductase Inhibitors: Statins as Antiinflammatory Agents? Circulation, June 1, 2004; 109(21_suppl_1): II-18 - II-26. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. R. DANESH and Y. S. KANWAR Modulatory effects of HMG-CoA reductase inhibitors in diabetic microangiopathy FASEB J, May 1, 2004; 18(7): 805 - 815. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Viswambharan, X.-F. Ming, S. Zhu, A. Hubsch, P. Lerch, G. Vergeres, S. Rusconi, and Z. Yang Reconstituted High-Density Lipoprotein Inhibits Thrombin-Induced Endothelial Tissue Factor Expression Through Inhibition of RhoA and Stimulation of Phosphatidylinositol 3-Kinase but not Akt/Endothelial Nitric Oxide Synthase Circ. Res., April 16, 2004; 94(7): 918 - 925. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Abe, H. Shimokawa, K. Morikawa, T. Uwatoku, K. Oi, Y. Matsumoto, T. Hattori, Y. Nakashima, K. Kaibuchi, K. Sueishi, et al. Long-Term Treatment With a Rho-Kinase Inhibitor Improves Monocrotaline-Induced Fatal Pulmonary Hypertension in Rats Circ. Res., February 20, 2004; 94(3): 385 - 393. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Minami, A. Sugiyama, S.-Q. Wu, R. Abid, T. Kodama, and W. C. Aird Thrombin and Phenotypic Modulation of the Endothelium Arterioscler. Thromb. Vasc. Biol., January 1, 2004; 24(1): 41 - 53. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. P. Jones, Y. Teshima, M. Akao, and E. Marban Simvastatin Attenuates Oxidant-Induced Mitochondrial Dysfunction in Cardiac Myocytes Circ. Res., October 17, 2003; 93(8): 697 - 699. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R.P. Brandes, S. Beer, T. Ha, and R. Busse Withdrawal of Cerivastatin Induces Monocyte Chemoattractant Protein 1 and Tissue Factor Expression in Cultured Vascular Smooth Muscle Cells Arterioscler. Thromb. Vasc. Biol., October 1, 2003; 23(10): 1794 - 1800. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. P. Tracy Thrombin, Inflammation, and Cardiovascular Disease: An Epidemiologic Perspective Chest, September 1, 2003; 124(3_suppl): 49S - 57S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Takano, K. Mizuno, S. Yokoyama, K. Seimiya, F. Ishibashi, K. Okamatsu, and R. Uemura Changes in coronary plaque color and morphology by lipid-lowering therapy with atorvastatin: serial evaluation by coronary angioscopy J. Am. Coll. Cardiol., August 20, 2003; 42(4): 680 - 686. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Branger, B. van den Blink, S. Weijer, A. Gupta, S. J.H. van Deventer, C. E. Hack, M. P. Peppelenbosch, and T. van der Poll Inhibition of coagulation, fibrinolysis, and endothelial cell activation by a p38 mitogen-activated protein kinase inhibitor during human endotoxemia Blood, June 1, 2003; 101(11): 4446 - 4448. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Waehre, J. K. Damas, L. Gullestad, A. M. Holm, T. R. Pedersen, K. E. Arnesen, H. Torsvik, S. S. Froland, A. G. Semb, and P.a. Aukrust Hydroxymethylglutaryl coenzyme a reductase inhibitors down-regulate chemokines and chemokine receptors in patients with coronary artery disease J. Am. Coll. Cardiol., May 7, 2003; 41(9): 1460 - 1467. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Ishibashi, T. Sakamoto, H. Ohkawara, K. Nagata, K. Sugimoto, S. Sakurada, N. Sugimoto, A. Watanabe, K. Yokoyama, N. Sakamoto, et al. Integral Role of RhoA Activation in Monocyte Adhesion-Triggered Tissue Factor Expression in Endothelial Cells Arterioscler. Thromb. Vasc. Biol., April 1, 2003; 23(4): 681 - 687. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Rezaie-Majd, G. W. Prager, R. A. Bucek, G. H. Schernthaner, T. Maca, H.-G. Kress, P. Valent, B. R. Binder, E. Minar, and M. Baghestanian Simvastatin Reduces the Expression of Adhesion Molecules in Circulating Monocytes From Hypercholesterolemic Patients Arterioscler. Thromb. Vasc. Biol., March 1, 2003; 23(3): 397 - 403. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Kluft, R. Kleemann, and M.P.M. de Maat How best to counteract the enemies? By controlling inflammation in the coronary circulation Eur. Heart J. Suppl., November 1, 2002; 4(suppl_G): G53 - G65. [Abstract] [PDF]
|
|
|
|
|
|
A. C. Yeung and P. Tsao Statin Therapy: Beyond Cholesterol Lowering and Antiinflammatory Effects Circulation, June 25, 2002; 105(25): 2937 - 2938. [Full Text] [PDF]
|
|